Brassica Pharma Faces Second FDA Recall for Eye Ointment Sterility, Escalating Supply Chain Risk
Brassica Pharma Pvt Ltd faces a Class II FDA recall for 159,334 units of CVS Health Lubricant Eye Ointment due to a lack of sterility assurance. This follows a similar recall for Equate Eye Ointment, signaling systemic quality control deficiencies at its Thane, India facility. Procurement and regulatory teams must reassess Brassica Pharma as a supplier, given the recurring sterility concerns impacting critical ophthalmic products distributed in the U.S.
FDA Class II Recall: Sterility Failure in CVS Health Lubricant Eye Ointment
Brassica Pharma Pvt Ltd, an India-based manufacturer, has initiated a voluntary, firm-initiated Class II recall (D-0353-2024) for 159,334 units of CVS Health Lubricant Eye Ointment. The critical reason for this recall is a "Lack of Assurance of Sterility," a significant concern for any ophthalmic product. The affected product, containing Mineral oil 31.9% and White petrolatum 57.7% as emollients, is packaged in 3.5-gram tubes and was distributed nationwide within the United States by CVS Pharmacy, Inc., based in Woonsocket, RI. The recall, initiated on January 30, 2024, covers specific lots: A2F03 (Exp. May-24), A2I02 (Exp. Aug-24), A2L02 (Exp. Nov-24), A3C04 (Exp. Feb-25), and A3H04 (Exp. Jul-25). For procurement directors and supply chain VPs, this event necessitates immediate action to quarantine affected stock and assess inventory levels. The potential for non-sterile products to cause serious eye infections means regulatory affairs teams must ensure all compliance protocols are rigorously followed, including reporting and product disposition. Business development executives should note the impact on brand reputation for distributors like CVS Pharmacy, Inc., underscoring the critical need for robust supplier qualification and oversight in the pharmaceutical sector.
Brassica Pharma's Manufacturing Profile and Geographic Risk
Brassica Pharma Pvt Ltd operates its manufacturing facility at Plot No. T-68, T 68 (Pt), T-63, Midc, Tarapur, Boisar, Thane, India. As a manufacturer, its role in the global supply chain, particularly for over-the-counter (OTC) ophthalmic products, is significant, with its products reaching the U.S. market. The current recall of CVS Health Lubricant Eye Ointment highlights the inherent risks associated with sourcing sterile products from facilities that exhibit recurring quality control issues. For procurement directors, understanding the geographic concentration of suppliers in regions like India is crucial for risk assessment. While India is a major hub for pharmaceutical manufacturing, incidents like this underscore the need for stringent due diligence on all international suppliers. Supply chain VPs must evaluate their dependency on single manufacturing sites or regions for critical formulations, especially those requiring aseptic conditions. This event signals that the regulatory scrutiny on facilities in Thane, India, particularly those producing sterile drugs, may intensify, potentially impacting other manufacturers in the vicinity.
Escalating Compliance Risk: A Pattern of Sterility Assurance Failures
This recall of CVS Health Lubricant Eye Ointment is not an isolated incident for Brassica Pharma Pvt Ltd. The company has a documented history of sterility assurance failures, notably a prior Class II recall involving 'Equate Eye Ointment' that impacted the Walmart supply chain. Both the current event (D-0353-2024) and the Equate recall are associated with the same prompt identifier, P-01, and were reported around March 6, 2024, strongly indicating a systemic issue within Brassica Pharma's quality management system at its Thane facility rather than a one-off manufacturing error. For regulatory affairs heads, this pattern is a critical red flag, suggesting fundamental deficiencies in environmental controls, aseptic processing, or quality control testing for sterile products. Procurement directors must recognize that a supplier with repeated sterility issues presents an unacceptable level of risk, not only for product quality but also for regulatory compliance and potential market withdrawal costs. Business development executives should factor this escalating compliance risk into any future partnership evaluations with Brassica Pharma, as such a history can significantly impact product launch timelines and market access.
Supply Chain Vulnerability and Downstream Impact on U.S. Retailers
The nationwide distribution of the recalled CVS Health Lubricant Eye Ointment within the United States, primarily through CVS Pharmacy, Inc., underscores the significant supply chain vulnerability. Given Brassica Pharma's prior recall of Equate Eye Ointment distributed via Walmart, it is evident that the company serves as a key manufacturer for major U.S. retail pharmacy chains for essential over-the-counter ophthalmic products. This concentration of supply from a single manufacturer, now demonstrating recurring sterility issues, creates a substantial single point of failure risk. Supply chain VPs must immediately assess the full scope of products sourced from Brassica Pharma across all their retail partners and private label brands. The direct impact includes potential stock-outs, increased logistics costs for returns and destruction, and damage to brand trust for the distributors. Regulatory affairs heads must ensure that all downstream partners are informed and compliant with recall procedures, mitigating further regulatory exposure. This situation highlights the imperative for diversified sourcing strategies to protect against disruptions originating from a single high-risk supplier.
Mitigating Risk: Strategic Sourcing and Enhanced Supplier Qualification
In light of Brassica Pharma's recurring sterility assurance failures, procurement directors must prioritize the identification and qualification of alternative suppliers for ophthalmic products. This process should involve a comprehensive re-evaluation of current supplier portfolios, focusing on manufacturers with robust quality management systems and a demonstrable track record of FDA compliance, particularly for sterile drug production. While specific alternative suppliers are not provided in the knowledge graph, the strategic imperative is to seek out geographically diverse manufacturing sites to reduce single-country risk. Qualification timelines for new sterile product manufacturers can be extensive, often spanning 12-24 months, making immediate action critical to prevent future supply disruptions. Supply chain VPs should initiate parallel qualification processes with multiple potential partners to build resilience. Business development executives should leverage this event to explore new partnerships that offer enhanced supply chain security and reduced regulatory exposure, ensuring continuity of critical product lines and safeguarding consumer health.
Regulatory Outlook and Future Implications for Brassica Pharma
The repeated sterility issues at Brassica Pharma Pvt Ltd's Thane facility are likely to trigger heightened scrutiny from the FDA. While the current action is a firm-initiated voluntary recall, a pattern of such failures often leads to more severe regulatory interventions, including official FDA Warning Letters, increased import surveillance, and potentially an Import Alert if the company fails to demonstrate effective remediation. Regulatory affairs heads should anticipate that Brassica Pharma will be required to submit a comprehensive corrective and preventive action (CAPA) plan addressing the root causes of the sterility assurance failures, which will be subject to rigorous FDA review and potential on-site inspections. For companies sourcing from Brassica Pharma, this means a significant risk of future supply disruptions due to potential regulatory actions against the manufacturer. Business development executives should be aware that such a compliance record can severely impact a company's ability to gain new market approvals or maintain existing ones, underscoring the long-term commercial ramifications of persistent quality control deficiencies in the global pharmaceutical supply chain.